Concise guidance: diagnosis and management of giant cell arteritis.
Giant cell arteritis (GCA) or temporal arteritis (TA) with polymyalgia rheumatica (PMR) is among the most common reasons for long-term steroid prescription. GCA is a critically ischaemic disease, the most common form of vasculitis and should be treated as a medical emergency. Visual loss occurs in up to a fifth of patients, which may be preventable by prompt recognition and treatment. The British Society for Rheumatology (BSR) and the British Health Professionals in Rheumatology (BHPR) have recently published guidelines on the management of PMR. The purpose of this concise guidance is to draw attention to the full guidelines to encourage the prompt diagnosis and urgent management of GCA, with emphasis on the prevention of visual loss. They provide a framework for disease assessment, immediate treatment and referral to specialist care for management and monitoring of disease activity, complications and relapse.
Dasgupta
Bhaskar
B
Essex University Southend University Hospital, Westcliff-on-Sea, Essex. bhaskar.dasgupta@southend.nhs.uk
D001241:Aspirin / Q000627:therapeutic use; D001766:Blindness / Q000209:etiology / Q000517:prevention & control; D003937:Diagnosis, Differential; D003952:Diagnostic Imaging; D042241:Early Diagnosis; D013700:Giant Cell Arteritis / Q000150:complications / Q000175:diagnosis* / Q000628:therapy*; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D020521:Stroke / Q000209:etiology / Q000517:prevention & control; D013699:Temporal Arteries / Q000473:pathology
D005938:Glucocorticoids; D010975:Platelet Aggregation Inhibitors; D001241:Aspirin